Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Q4 2025 Earnings Presentation
23 slides from Revenio Group Oyj's earnings presentation, Feb 11, 2026
Slide 1: 2025 Financial Statements Release
2025 Financial Statements Release February 11, 2026 1 11.2.2026 Revenio
Slide 2: Disclaimer
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio Group Corporation’s shares. Group's past performance is no guide to future performance, and persons needing advi
Slide 3: Today's presenters
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Today’s presenters Jouni Robin Toijala Pulkkinen CEO CFO 3 11.2.2026 Revenio
Slide 4: Agenda
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Agenda 1. Business highlights 2. Strategy period 2024-2026 recap 3. Financials for Q4/2025 and 2025 4. Financial guidance for 2026 5. Q&A 4 11.2.2026 Revenio
Slide 5: October-December highlights
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION October-December highlights • Net sales totaled EUR 31.2 (30.5) million, up by 2.2% Net sales EBIT • Currency-adjusted net sales increased by 8.6% • Sales in the US grew strongly and we reached an 31.2 6.7 MEUR (+2.2%) MEUR (-26.9%) all-time sales reco
Slide 6: January-December highlights
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION January-December highlights Net sales EBIT • Net sales developed favorably – reported net sales amounted to EUR 109.7 (103.5) million, an 109.7 25.4 increase of 6.0% MEUR (+6.0%) MEUR (+1.4%) • Currency-adjusted net sales increased by 9.1% • Profitabil
Slide 7: Strategy period 2024–2026 recap
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Strategy period 2024–2026 recap 7 11.2.2026 Revenio
Slide 8: Despite the geopolitical and economical turmoil megatrends support our growth
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Despite the geopolitical and economical turmoil megatrends support our growth The need for eye care Insufficient eye care We need smarter is growing globally workforces ways of working 8 11.2.2026 Revenio
Slide 9: Significant advancements in all strategic areas in 2025
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Significant advancements in all strategic areas in 2025 Improve the quality of clinical • Sales started for the new iCare MAIA microperimeter diagnostics with targeted • iCare ALTIUS, cloud-based ophthalmic data management solution, launched in product
Slide 10: Our key priorities 2026
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Our key priorities 2026 Our growth pathway 2024–2026 We invest in R&D We expand our We develop further We continue search Our ESG program to launch new offering to non- customer for selected is maturing, and we and exciting traditional eye care experie
Slide 11: Strategy period 2027-2030
Strategy period 2027-2030 The implementation of our strategy is progressing with determination in all our focus areas towards the end of our strategy period at the end of 2026. We will organize a Capital Markets Day (CMD) in the fall of 2026. At the event, we will discuss our ongoing strategy update
Slide 12: Financials Q4/2025 and 2025
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Financials Q4/2025 and 2025 12 11.2.2026 Revenio
Slide 13: Development of Revenio's key figures
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Development of Revenio’s key figures MEUR 10-12/ 10-12/ Change 1-12/ 1-12/ Change 2025 2024 -% 2025 2024 -% • The gross margin was affected Net sales 31.2 30.5 2.2 109.7 103.5 6.0 by tariffs and the delayed price Gross margin 21.1 21.7 -2.7 77.8 72.9 6
Slide 14: Good finish for the year
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Good finish for the year Net sales (EUR million) • The currency-adjusted net 35 sales for the fourth quarter 30,5 31,2 increased by 8.6% 30 29,1 28,3 26,1 26,5 25,9 • Sales in the fourth quarter 25,4 25 23,6 23,9 were primarily driven by our 23,2 22,3
Slide 15: Profitability affected by tariffs and FX changes
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Profitability affected by tariffs and FX changes • FX headwind (topline) was Adjusted operating profit EUR million and % (EBIT) approximately EUR 1 million in 10 9,5 35 9,3 9,3 the last quarter and EUR 2.4 9 million for the entire year 30 8 • Clinical
Slide 16: Balance sheet remains unlevered
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Balance sheet remains unlevered 90% 80% 76,2 % 76,1 % 72,7 % 70% 66,8 % 63,0 % 60% 50% 40% 30,6 % 29,7 % 28,2 % 28,3 % 30% 25,1 % 24,2 % 22,4 % 23,5 % 22,1 % 19,9 % 20% 10% 0% -1,0 % -3,6 % -10% -7,3 % -13,1 % -13,3 % -20% 2021 2022 2023 2024 2025 Equi
Slide 17: Balance sheet stays unlevered
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Balance sheet stays unlevered Equity ratio and net gearing (%) 90 4 80,2 79,6 80 76,3 76,2 77,2 76,1 2 74,5 74,7 71,1 72,2 72,7 • Equity ratio remains high 70 66,8 0 64 -2 60 • Net gearing fell to –13.3% 50 -4 driven by strong cashflow -6 40 -8 30 -10
Slide 18: Cash flow from operations was historically strong
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Cash flow from operations was historically strong Cash flow from operations (EUR million) 18 15,9 16 • Cash flow from operations 14 strengthened, particularly due 11,7 to efficient working capital 12 management and lower tax 9,8 10 payments compared to
Slide 19: Strong financial development has enabled a steadily increasing dividend
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Strong financial development has enabled a steadily increasing dividend 0,50 140% 0,45 0,44 120% • The Board of Directors will 0,40 0,40 105,8 % 0,38 propose to the Annual General 0,34 0,36 100% Meeting of April 15, 2026, that 0,35 0,32 the General Mee
Slide 20: Shareholders on December 31, 2025
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Shareholders on December 31, 2025* No. of shares % Verified Ownership 1. William Demant Invest A/S 6,532,461 24.48% 2025-12-30 2. SEB Funds 1,220,695 4.58% 2025-12-31 3. Vanguard 884,038 3.31% 2025-12-31 4. Ilmarinen Mutual Pension 803,118 3.01% 2025-1
Slide 21: Financial guidance for 2026
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Financial guidance for 2026 Revenio Group’s exchange rate-adjusted net sales are estimated to grow 8-15 percent from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level. 21 11.2.2026 Revenio
Slide 22: Q&A
FINANCIAL STATEMENTS 2025 - RESULT PRESENTATION Q&A 22 11.2.2026 Revenio
Slide 23: REVENIO
REVENIO